Macrophage Activation Modulator Screening With M1/M2 Phenotype Shifts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulation of macrophage polarization contributes to various human diseases, including cancer, fibrosis, obesity, diabetes, and inflammatory and neurodegenerative diseases, necessitating the identification of modulators to intervene in macrophage activation.
Innovation Solution
A method of identifying modulators of macrophage activation by contacting primary macrophage cells with candidate agents and monitoring morphology changes, using tools like fluorescence microscopes or Opera Phenix high content screening systems, to induce M1-like or M2-like macrophage phenotypes, which can treat diseases through pro-inflammatory, anti-inflammatory, or tissue repair responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If macrophage polarization is left unchecked to maintain tissue homeostasis, then tissue repair and immunity are preserved, but dysregulation contributes to multiple human diseases including cancer, fibrosis, obesity, diabetes, and inflammatory diseases
Solution Approach 1:
The patent identifies and modulates specific molecular parameters (cytoskeletal proteins, signaling pathways, transcription factors) that control macrophage polarization. By changing these parameters through targeted compounds, the macrophage phenotype can be shifted between M1 and M2 states, allowing maintenance of tissue homeostasis while preventing disease-associated dysregulation.
Solution Approach 2:
The patent introduces intermediary compounds and molecules that mediate macrophage polarization. These include cytochalasin-B, fenbendazole, parbendazole, methiazole, alprostadil, FTY720, penfluridol, taxol, smer-3, cantharidin, SCH79797, mitoxantrone, niclosamide, MS275, HMN-214, DPI, thiostrepton, evodiamine, cucurbitacin-I, NVP 231, Chlorhexidine, Diphenyleneiodonium, LE135, Fluvoxamine, Mocetinostat, Pimozide, NP-010176, Celastrol, FTY720, WP1130, and various other agents that act as intermediaries to control macrophage activation states.
2Reliability
If macrophage activation is highly regulated to prevent disease, then disease intervention is enabled, but identification of effective modulators becomes complex
Solution Approach 1:
The patent segments the complex process of macrophage modulation into identifiable components: specific molecular targets (cytoskeletal proteins, signaling molecules, transcription factors), distinct phenotypic states (M1, M2, M0), and measurable morphological changes. This segmentation allows systematic identification and testing of modulators against defined criteria.
Solution Approach 2:
The patent replaces complex mechanical/physical assessment methods with molecular and cellular-level analysis. Instead of observing macroscopic changes, the invention uses fluorescence microscopy, flow cytometry, and molecular biology techniques to detect and quantify macrophage polarization at the cellular and molecular level, simplifying the identification process.
3Adaptability or versatility
If multiple macrophage phenotypes are induced to treat different diseases, then therapeutic versatility is improved, but specificity and precision of treatment becomes more difficult to achieve
Solution Approach 1:
The patent applies local quality by targeting specific macrophage subpopulations in specific tissue contexts with disease-appropriate phenotypes. Rather than applying a universal treatment, the invention identifies and induces specific M1 or M2 phenotypes in macrophages located at disease-relevant sites, such as tumor-associated macrophages in cancer or tissue-resident macrophages in fibrosis, achieving both versatility and precision.
Data Source
AI summary
Disclosed are methods of modulating macrophage activation to treat various diseases, such as cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases. Also disclosed are methods of identifying compounds useful for modulating macrophage activation as means to treat cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases.